Anosmia Clinical Trial
Official title:
Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients With COVID-19
Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients with COVID-19
AIM OF THE STUDY AND WORK PLAN COVID-19 Hospitalized patients with confirmed diagnosis of
disease will
1. undergo questionnaire for prevalence of Anosmia/dysgeusia
2. linking the anosmia/dysgeusia to the degree of disease and treatment outcomes.
3. looking to improvement in anosmia/dysgeusia and its timing,
METHODOLOGY Ethical committee approval for the current study protocol will be obtained.
Patients will be invited to participate and the informed consent will be signed.
Subjects and Setting:
The clinical data of 218 patients with laboratory-confirmed COVID-19 infection will be
collected from Ain Shams University Hospitals. In addition, other patients, infected
physicians and nurses may voluntarily enroll in the study. Comorbidities as diabetes mellitus
or hypertension, and chronic treatment lines taken will be documented, and considered in the
analysis of the data. Patients would be receiving the ASU treatment protocol for covid 19.
The following inclusion criteria will be considered: adult (>18 year); laboratory-confirmed
COVID-19 infection (reverse transcription polymerase chain reaction, RT-PCR). The following
exclusion criteria will be considered: patients with olfactory or gustatory dysfunctions
before the epidemic; patients without a laboratory-confirmed COVID-19 infection diagnosis;
patients who were in the intensive care unit at the time of the study (due to their health
status).
Clinical Outcomes Clinical data will be collected during the ear, nose, and throat (ENT)
consultation; in the patient's room.
Questions about olfactory function; questions investigating gustatory function; and questions
about the treatment of the COVID-19 infection. All patients will be asked to answer these
questions.
Olfactory and Gustatory Outcomes The occurrence of olfactory dysfunction has been identified
through several questions including social, eating, annoyance, and anxiety questions. The
rest of the olfactory and gustatory questions will be based on the smell and taste. The
questions have been chosen to characterize the variation, timing and associated-symptoms of
both olfactory and gustatory dysfunctions, and, therefore, they suggest a potential etiology.
Also the mean recovery time of olfaction will be assessed through 4 defined propositions: 1-4
days; 5-8 days; 9-14 days and >15 days.
Statistical Analysis First, the following descriptive analysis will be done: frequency,
percentages, mean and standard deviation (SD). Thereafter, a comparison will be done using
Student t-test for quantitative variables and Fisher exact test for qualitative variables.
Statistical Package Data entry and statistical analysis will be done using Statistical
Package for Social Science (SPSS) version 20.0.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04964414 -
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Completed |
NCT05445921 -
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02179554 -
Does Cardiopulmonary Bypass Change Olfaction?
|
||
Completed |
NCT04957563 -
Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia
|
N/A | |
Terminated |
NCT03680911 -
NAC for Head Trauma-induced Anosmia
|
Phase 3 | |
Completed |
NCT04657809 -
Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia
|
Phase 2 | |
Completed |
NCT04853836 -
Olfactory Disfunction and Co-ultraPEALut
|
Phase 4 | |
Recruiting |
NCT05040659 -
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
|
||
Recruiting |
NCT05562050 -
Characteristics of the Anosmic Olfactory Mucosa
|
||
Completed |
NCT05152030 -
The Clinical Applicability of the 'TIB' Olfactory Test Device
|
||
Recruiting |
NCT05384561 -
Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19
|
N/A | |
Enrolling by invitation |
NCT04764981 -
Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19)
|
N/A | |
Withdrawn |
NCT04408391 -
Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
|
||
Completed |
NCT04361474 -
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
|
Phase 3 | |
Completed |
NCT03990766 -
Smell Changes & Efficacy of Nasal Theophylline
|
Phase 2 | |
Completed |
NCT04797936 -
BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19
|
Phase 4 | |
Recruiting |
NCT04528329 -
Anosmia and / or Ageusia and Early Corticosteroid Use
|
Phase 4 | |
Completed |
NCT04789499 -
Smell in Covid-19 and Efficacy of Nasal Theophylline
|
Phase 2 | |
Recruiting |
NCT04384042 -
Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
|